Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
perfluoro-tert-butylcyclohexane
- Development stage
- Phase 2
- Lead developer
- Tenex Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Perfluoro-tert-butylcyclohexane is a synthetic perfluorocarbon (PFC) emulsion developed as an intravenous oxygen carrier. Originally advanced by Oxygen Biotherapeutics (now Tenax Therapeutics) under the brand name Oxycyte, the compound is chemically inert and possesses a high capacity for dissolving respiratory gases, particularly oxygen. Its primary therapeutic mechanism involves enhancing oxygen delivery to tissues in conditions where blood flow or oxygenation is compromised, such as traumatic brain injury (TBI), hemorrhagic shock, and decompression sickness. Additionally, due to the presence of fluorine atoms, it has been investigated as a diagnostic imaging agent (ABL-101) for mapping inflammation in atherosclerotic plaques using Fluorine-19 Magnetic Resonance Imaging (19F-MRI). Clinical development for TBI reached Phase IIb but was suspended by Tenax in 2014 due to safety concerns regarding thrombocytopenia and immune system interactions, leading to the termination of the program in 2015.
- Brand names
- Oxycyte
- Other names
- PFTBCHPerfluoro tert-butylcyclohexanePerfluorotertbutylcyclohexane
Beyond the preview
Go deeper on perfluoro-tert-butylcyclohexane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on perfluoro-tert-butylcyclohexane.